<DOC>
	<DOCNO>NCT00027534</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell treat laboratory may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy treat patient advanced metastatic cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety feasibility active immunotherapy comprise autologous dendritic cell infect recombinant fowlpox-CEA-TRICOM vaccine patient advance metastatic malignancy express CEA . - Assess CEA-specific immune response patient treat regimen . - Assess , preliminary manner , clinical response rate patient treat regimen . OUTLINE : This dose-escalation study . Autologous dendritic cell ( ADCs ) harvest infected fowlpox-CEA-TRICOM vaccine . Patients receive infect ADCs intradermally subcutaneously ( SC ) follow ADCs mixed CMV pp65 peptide ADCs mixed tetanus toxoid SC intradermally day 1 . Treatment repeat every 3 week total 4 , 8 , 12 immunization absence unacceptable toxicity . Cohorts 6 patient receive escalate number immunization maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 6-18 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic malignancy express CEA Metastatic disease meet one follow criterion : Measurable nonmeasurable History metastasis current evidence disease , meet one follow criterion : Unresectable peritoneal lymph node metastasis detect image Treated resect metastatic disease consider high risk recurrence ( predict 5year diseasefree survival le 50 % ) Must complete treatment render evidence disease within past year CEAexpressing malignancy define follow : Immunohistochemical staining ( least 50 % tumor least moderate intensity stain ) CEA level peripheral blood great 2.5 Âµg/L Tumor know universally CEA positive ( e.g. , colon rectal cancer ) Received prior therapy possible survival benefit refuse therapy Prior resection brain metastasis allow provided metastasis CT scan MRI brain within 1 month enrollment Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status Karnofsky 70100 % Life expectancy More 6 month Hematopoietic WBC least 3,000/mm^3 Absolute lymphocyte count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL ( transfusion epoetin alfa allow ) Hepatic Bilirubin le 2.0 mg/dL SGOT/SGPT le 1.5 time upper limit normal No active acute chronic viral hepatitis Hepatitis B surface antigen negative Hepatitis C negative No hepatic disease would preclude study entry Renal Creatinine le 2.5 mg/dL No active acute chronic urinary tract infection Cardiovascular No New York Heart Association class III IV heart disease Immunologic HIV negative No history autoimmune disease , include , limited , follow : Inflammatory bowel disease Systemic lupus erythematosus Rheumatoid arthritis Ankylosing spondylitis Scleroderma Multiple sclerosis No allergy egg component study vaccine Other No active acute chronic infection No concurrent serious acute chronic illness would preclude study entry No medical psychological impediment would preclude study entry No malignancy within past 5 year except nonmelanoma skin cancer , control carcinoma situ cervix , control superficial bladder cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior biologic therapy recover No concurrent immunotherapy Chemotherapy At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy At least 4 week since prior hormonal therapy recover At least 6 week since prior steroid except steroid use premedication chemotherapy contrastenhanced study No concurrent steroid Radiotherapy Prior palliative radiotherapy ( include systemic radiolabeled compound ) unstable painful bone metastasis weightbearing bone may allow At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery Not specify Other At least 4 week since prior therapy ( include experimental therapy ) recover No concurrent immunosuppressives ( e.g. , azathioprine cyclosporine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>Paget disease breast intraductal carcinoma</keyword>
	<keyword>Paget disease breast invasive ductal carcinoma</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>diffuse adenocarcinoma stomach</keyword>
	<keyword>intestinal adenocarcinoma stomach</keyword>
	<keyword>mixed adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>